Human CEACAM-6 / CD66c Protein, His Tag
分子別名(Synonym)
CEACAM6,CD66c,CEAL,NCA
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human CEACAM-6, His Tag (CE6-H5223) is expressed from human 293 cells (HEK293). It contains AA Lys 35 - Gly 320 (Accession # NP_002474.3).
Predicted N-terminus: Lys 35
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 32.0 kDa. The protein migrates as 45-65 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
癌胚抗原相關(guān)細(xì)胞粘附分子6(非特異性交叉反應(yīng)抗原)(CEACAM6)也稱為CD66c(分化簇66c)、CEAL、NCA,是免疫球蛋白超家族中的七個(gè)人類(lèi)CEACAM家族成員之一。在人類(lèi)中,CEACAMs包括I型跨膜蛋白(CEACAM1、CEACAM3和CEACAM4)和GPI連接分子(CEACAM5至CEACAM8)。沒(méi)有人類(lèi)CEACAM2。CEACAM 6包含一個(gè)N端V型Ig樣結(jié)構(gòu)域(N結(jié)構(gòu)域),后面是兩個(gè)C2型Ig樣域。它顯示出相當(dāng)大的糖基化,包括(唾液酸基)LewisX,它介導(dǎo)與E-選擇素、半乳凝素和一些細(xì)菌膜的結(jié)合。CEACAM-6由粒細(xì)胞及其祖細(xì)胞表達(dá)。它也由各種器官的上皮細(xì)胞表達(dá),在胰腺癌和結(jié)腸癌以及增生性息肉中上調(diào)。在CEACAM6過(guò)表達(dá)的情況下,腫瘤細(xì)胞對(duì)粘附相關(guān)凋亡具有抗性。
關(guān)鍵字: CEACAM-6;CEACAM6蛋白;CD66c蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。